BRONZE

Cergentis

Cergentis is a privately held genomics company and has developed and patented the Targeted Locus Amplification (TLA) technology. TLA is a widely published Next Generation Sequencing (NGS) technology that offers unique advantages in the implementation of advanced genetic engineering.


We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provides services for the support in R&D in these fields. Founded in 2012, Cergentis has established itself as a trusted partner and leader in robust and rapid genetic characterization of genetically engineered cell lines, cell and gene therapy products and transgenic (animal) models for the global biopharmaceutical industry as well as leading research institutes worldwide. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.